Has Teva Pharmaceutical Industries received FDA approval? Track FDA approvals, PDUFA dates, and regulatory milestones for TEVA with the latest event history at MarketBeat.

Teva Pharmaceutical Industries stock had a USD 45,432,606,400 market value on September 23, 2026. Se

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) was the recipient of a large increase in short interest in the month of September. As of September 15th, there was short interest totaling 31,478,314 shares, an increase of 11,467.5% from the August 31st total of 272,128 shares. Based on an average daily volume of 1,150,992 shares, the short-interest ratio is presently 27.3 days. Approximately 2.7% of the shares of the stock are short sold.

Teva released its Q3 2026 Aide Memoire to aid investor preparation. The document aggregates prior public disclosures and management commentary. Q3 2026 financial results are scheduled for release on November 3, 2026.

Teva Pharmaceutical Industries will announce Q3 2026 financial results on November 3, 2026, with a c

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Moody's eleva la calificación crediticia de Teva Pharmaceutical a Baa3, lo que refleja una exitosa estrategia de crecimiento

Participants must register in advance for phone access; the live webcast will be on Teva's website, with a replay available within 24 hours.

Oppenheimer assumed coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday. They set an "outperform" rating and a $50.00 price objective on the stock.

Teva Pharmaceutical Industries (NYSE:TEVA) is back on investors’ radar after its U.S. affiliate presented new Phase 3 SOLARIS data on investigational olanzapine LAI TEV-749 for adults with schizophrenia. TEVA’s share price has climbed 18.79% year to date, and the latest 30-day share price return of 5.43% suggests momentum is still building around Teva Pharmaceutical Industries as investors weigh the SOLARIS data alongside a 95.05% 1-year total shareholder return and very strong 3 and 5-year...